**

Overview

Bipolar disorder (formerly called manic‑depressive illness) is a neuropsychiatric condition that affects roughly 1–2 % of the global population. Individuals experience distinct mood episodes that can last from days to several weeks, and in some cases, months. A depressive episode is characterized by persistent sadness, loss of interest, fatigue, crying, negative self‑view, and often reduced eye contact. In contrast, a manic episode involves an abnormally high or irritable mood, inflated self‑esteem, decreased need for sleep, rapid speech, racing thoughts, and reckless behaviors such as overspending or unsafe driving. When the elevated mood is milder, does not cause marked functional impairment, and lasts at least four days, it is termed hypomania.

The disorder is highly heterogeneous: some people cycle rapidly (multiple episodes per year), while others have long periods of stability between episodes. Sleep disruption is a hallmark of manic phases, with patients often feeling rested after only a few hours. The emotional volatility of BD contributes to a strikingly high risk of suicide—about 15–20 % of individuals with BD die by suicide, and 30–60 % attempt it at least once. Self‑harm behaviors are also common, affecting 40–50 % of all patients and up to 78 % of adolescents with the condition. Early recognition and comprehensive treatment are essential to reduce morbidity and mortality.

History/Background

The concept of alternating mood states dates back to ancient Greek physicians such as Hippocrates, who described “melancholia” and “mania” as separate illnesses. In the 19th century, French psychiatrist Jean-Pierre Falret coined the term “circular insanity” to capture the recurrent nature of mood swings. German psychiatrist Emil Kraepelin later distinguished manic‑depressive illness from schizophrenia, emphasizing its episodic course and biological underpinnings—a classification that persisted for decades.

The mid‑20th century saw the introduction of lithium, the first mood‑stabilizing medication, dramatically improving outcomes and cementing BD as a treatable medical disorder. The 1970s and 1980s brought the development of anticonvulsants (e.g., valproate) and atypical antipsychotics, expanding the therapeutic arsenal. Diagnostic criteria were refined in successive editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), with the current DSM‑5 distinguishing Bipolar I, Bipolar II, and cyclothymic disorder based on severity and duration of manic versus hypomanic episodes. Research into genetics, neuroimaging, and circadian biology continues to shape modern understanding.

Key Information

- Epidemiology: Affects ~1–2 % of adults worldwide; onset typically occurs in late adolescence or early adulthood, though pediatric cases are increasingly recognized. - Subtypes: - Bipolar I: At least one full mania episode (may be preceded or followed by depression). - Bipolar II: At least one hypomania episode and one major depressive episode, without full mania. - Cyclothymic disorder: Chronic, milder mood fluctuations that do not meet full criteria for mania or depression. - Risk factors: Family history, certain genetic markers, stressful life events, substance misuse, and sleep‑wake rhythm disruptions. - Diagnosis: Clinical interview, standardized rating scales (e.g., Young Mania Rating Scale, Montgomery‑Åsberg Depression Rating Scale), and exclusion of medical mimics (thyroid disease, neurologic disorders). - Treatment: A multimodal approach combining mood stabilizers (lithium, valproate, lamotrigine), atypical antipsychotics, psychotherapy (cognitive‑behavioral therapy, interpersonal‑social rhythm therapy), and lifestyle interventions (regular sleep, exercise, stress management). Psychoeducation and adherence monitoring are critical to prevent relapse. - Prognosis: With optimal treatment, many individuals achieve sustained remission and functional recovery, though the disorder is lifelong and relapse rates remain significant.

Important: If you or someone you know exhibits signs of mania, severe depression, or suicidal thoughts, seek professional mental‑health care immediately. Early intervention can save lives.

Significance

Bipolar disorder’s impact extends beyond the individual to families, workplaces, and health systems. The high rates of suicide and self‑harm underscore a public‑health imperative for early detection, destigmatization, and accessible treatment. Economically, BD contributes to lost productivity, increased health‑care utilization, and substantial societal costs. Advances in pharmacogenomics and digital mood‑tracking tools hold promise for personalized care, while ongoing research into circadian biology may yield novel preventive strategies. Understanding BD also informs broader neuroscience, shedding light on the neural circuits that regulate emotion, reward, and cognition. Ultimately, comprehensive management of bipolar disorder improves quality of life, reduces mortality, and fosters societal inclusion for those living with this complex condition.

INFOBOX:
- Name: Bipolar disorder
- Type: Mental health / Mood disorder
- Date: First formally described in the late 19th century (Kraepelin, 1899)
- Location: Global prevalence (affects individuals worldwide)
- Known For: Alternating episodes of depression and elevated mood (mania/hypomania), high suicide risk, and response to mood‑stabilizing medications

TAGS: bipolar disorder, mania, hypomania, depression, suicide risk, mood stabilizer, mental health, psychiatric epidemiology